COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development
Open Access
- 1 January 2023
- journal article
- review article
- Published by Wiley in BioMed Research International
- Vol. 2023 (1) , 1879554
Abstract
The world is presently in crisis facing an outbreak of a health‐threatening microorganism known as COVID‐19, responsible for causing uncommon viral pneumonia in humans. The virus was first reported in Wuhan, China, in early December 2019, and it quickly became a global concern due to the pandemic. Challenges in this regard have been compounded by the emergence of several variants such as B.1.1.7, B.1.351, P1, and B.1.617, which show an increase in transmission power and resistance to therapies and vaccines. Ongoing researches are focused on developing and manufacturing standard treatment strategies and effective vaccines to control the pandemic. Despite developing several vaccines such as Pfizer/BioNTech and Moderna approved by the U.S. Food and Drug Administration (FDA) and other vaccines in phase 4 clinical trials, preventive measures are mandatory to control the COVID‐19 pandemic. In this review, based on the latest findings, we will discuss different types of drugs as therapeutic options and confirmed or developing vaccine candidates against SARS‐CoV‐2. We also discuss in detail the challenges posed by the variants and their effect on therapeutic and preventive interventions.Keywords
This publication has 291 references indexed in Scilit:
- The Double-Edged Sword: How Evolution Can Make or Break a Live-Attenuated Virus VaccineEvolution: Education and Outreach, 2011
- The BCG World Atlas: A Database of Global BCG Vaccination Policies and PracticesPLOS Medicine, 2011
- Assembly of Hybrid Bacteriophage Qβ Virus-like ParticlesBiochemistry, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Kinetics of Recombinant Adenovirus Type 5, Vaccinia Virus, Modified Vaccinia Ankara Virus, and DNA Antigen Expression In Vivo and the Induction of Memory T-Lymphocyte ResponsesClinical and Vaccine Immunology, 2008
- Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape MutantsPLOS Medicine, 2006
- Gene-based vaccines: recent technical and clinical advancesTrends in Molecular Medicine, 2006
- A human SARS-CoV neutralizing antibody against epitope on S2 proteinBiochemical and Biophysical Research Communications, 2005
- Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome CoronavirusJournal of Virology, 2005
- Ivermectin: An updateParasitology Today, 1985